Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 10, 2013
Event: Receipt of tentative FDA approval for Trokendi XR.
Key Financial Metrics
This filing is a current report regarding a regulatory event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the receipt of a tentative approval letter from the U.S. Food & Drug Administration (FDA) for Trokendi XR, a novel once-daily extended-release formulation of topiramate. The FDA completed its review of the New Drug Application as amended in December 2012.
Outlook, Risks, and Management Commentary
- Regulatory Status: The product is tentatively approved for use as recommended in the submitted and agreed-upon labeling.
- Next Steps: The filing references a press release (Exhibit 99.1) for further details but does not explicitly state commercial launch dates or specific risks in the body text provided.
Investor Verification Checklist
- Verify the conditions attached to the "tentative" approval status and the timeline for final approval.
- Review the attached press release (Exhibit 99.1) for commercialization plans and market strategy.
- Confirm the specific labeling requirements agreed upon with the FDA.
- Check subsequent filings for updates on the transition from tentative to final approval.